Research Analysts Offer Predictions for ARCT FY2025 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of Arcturus Therapeutics in a note issued to investors on Tuesday, August 12th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the biotechnology company will earn ($3.02) per share for the year, up from their previous estimate of ($3.10). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. Cantor Fitzgerald also issued estimates for Arcturus Therapeutics’ FY2026 earnings at ($3.77) EPS.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.77. The company had revenue of $28.30 million for the quarter, compared to analysts’ expectations of $17.64 million. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%.

A number of other analysts also recently weighed in on the stock. Canaccord Genuity Group reduced their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. Citigroup reaffirmed a “buy” rating and set a $49.00 price objective (up from $47.00) on shares of Arcturus Therapeutics in a report on Tuesday. Scotiabank reiterated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Wall Street Zen upgraded shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Wells Fargo & Company lowered their price objective on shares of Arcturus Therapeutics from $45.00 to $42.00 and set an “overweight” rating for the company in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.00.

Arcturus Therapeutics Stock Up 0.1%

Shares of ARCT opened at $19.23 on Thursday. The company’s fifty day moving average is $13.44 and its 200-day moving average is $13.31. Arcturus Therapeutics has a 12 month low of $8.04 and a 12 month high of $25.88. The firm has a market cap of $522.29 million, a price-to-earnings ratio of -8.62 and a beta of 2.26.

Institutional Trading of Arcturus Therapeutics

A number of large investors have recently bought and sold shares of ARCT. Kennedy Capital Management LLC lifted its position in Arcturus Therapeutics by 4.9% in the 2nd quarter. Kennedy Capital Management LLC now owns 11,674 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 544 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Arcturus Therapeutics by 5.0% during the 4th quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company’s stock worth $316,000 after buying an additional 883 shares in the last quarter. Tocqueville Asset Management L.P. lifted its position in shares of Arcturus Therapeutics by 4.5% during the 1st quarter. Tocqueville Asset Management L.P. now owns 23,400 shares of the biotechnology company’s stock worth $248,000 after buying an additional 1,000 shares in the last quarter. Virtus ETF Advisers LLC lifted its position in shares of Arcturus Therapeutics by 38.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock worth $69,000 after buying an additional 1,132 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Arcturus Therapeutics by 9.2% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,693 shares of the biotechnology company’s stock worth $156,000 after buying an additional 1,232 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.